IDT Australia Limited announced successful manufacture of the mRNA Drug Product. The Drug Product has met all specifications and is now progressing through the release process to be supplied to MIPS for use in their upcoming clinical trial. Successful manufacture signifies the completion of the material elements of the Master Services Agreement and Services Order, with ongoing product stability testing the only remaining item.